William Blair Has Optimistic Outlook of CRGX Q1 Earnings

CARGO Therapeutics, Inc. (NASDAQ:CRGX) – Investment analysts at William Blair boosted their Q1 2025 earnings per share (EPS) estimates for shares of CARGO Therapeutics in a research note issued on Thursday, January 30th. William Blair analyst S. Corwin now anticipates that the company will post earnings of ($0.66) per share for the quarter, up from their previous estimate of ($0.95). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for CARGO Therapeutics’ current full-year earnings is ($3.73) per share. William Blair also issued estimates for CARGO Therapeutics’ Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.34) EPS and FY2025 earnings at ($1.77) EPS.

CRGX has been the topic of several other reports. Jefferies Financial Group lowered CARGO Therapeutics from a “buy” rating to a “hold” rating and reduced their target price for the stock from $32.00 to $3.00 in a report on Thursday. Piper Sandler lowered CARGO Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $34.00 to $4.00 in a research report on Thursday. Chardan Capital downgraded shares of CARGO Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday. HC Wainwright cut shares of CARGO Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday. Finally, JPMorgan Chase & Co. downgraded shares of CARGO Therapeutics from an “overweight” rating to an “underweight” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company. According to MarketBeat.com, CARGO Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $15.00.

CARGO Therapeutics Stock Up 6.2 %

Shares of CRGX stock opened at $3.60 on Monday. CARGO Therapeutics has a 12-month low of $3.00 and a 12-month high of $33.92. The firm has a fifty day moving average of $14.27 and a 200-day moving average of $17.22. The firm has a market capitalization of $165.71 million, a price-to-earnings ratio of -0.85 and a beta of 2.50.

CARGO Therapeutics (NASDAQ:CRGX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.26.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CRGX. Brooklyn Investment Group bought a new position in CARGO Therapeutics in the fourth quarter valued at approximately $27,000. China Universal Asset Management Co. Ltd. bought a new position in shares of CARGO Therapeutics in the fourth quarter valued at $141,000. BNP Paribas Financial Markets increased its holdings in CARGO Therapeutics by 437.8% during the third quarter. BNP Paribas Financial Markets now owns 11,438 shares of the company’s stock worth $211,000 after buying an additional 9,311 shares during the last quarter. SG Americas Securities LLC bought a new stake in CARGO Therapeutics during the third quarter worth $234,000. Finally, JPMorgan Chase & Co. lifted its stake in CARGO Therapeutics by 74.9% in the third quarter. JPMorgan Chase & Co. now owns 15,007 shares of the company’s stock valued at $277,000 after acquiring an additional 6,426 shares during the last quarter. Institutional investors and hedge funds own 93.16% of the company’s stock.

CARGO Therapeutics Company Profile

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.